JP Morgan Chase
CLDX icon

JP Morgan Chase’s Celldex Therapeutics CLDX Stock Holding History

JP Morgan Chase’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,800
Closed -$299K – 7426
2024
Q3 		$299K Hold
8,800
– – ﹤0.01% 5203
2024
Q2 		$326K Hold
8,800
– – ﹤0.01% 4906
2024
Q1 		$369K Buy
+8,800
New +$361K ﹤0.01% 4990
2022
Q1 		– Sell
-141,000
Closed -$5.45M – 6631
2021
Q4 		$5.45M Hold
141,000
– – ﹤0.01% 2981
2021
Q3 		$7.61M Buy
+141,000
New +$6.62M ﹤0.01% 2656

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's CLDX Position: Q2 2026 in Review

JP Morgan Chase reduced its Celldex Therapeutics (CLDX) stake by 4.6% in Q2 2026, selling an estimated $243K and leaving 157,241 shares worth $6M. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

JP Morgan Chase first reported a position in CLDX in Q2 2013 and has held it in 51 quarters since. The position peaked at $11.4M in Q3 2021. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • JP Morgan Chase held 157,241 shares of Celldex Therapeutics worth $6M as of Q2 2026.
  • JP Morgan Chase sold 7,537 Celldex Therapeutics shares in Q2 2026, an estimated $243K.
  • Celldex Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3289 holding.
  • JP Morgan Chase first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's Celldex Therapeutics position peaked at $11.4M in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.